Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 21Leukemia 8Myelodysplastic Syndromes 7Recurrence 6Lymphoma 6Blast Crisis 5Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4Leukemia, Lymphocytic, Chronic, B-Cell 4Leukemia, Hairy Cell 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Lymphoma, Mantle-Cell 3Neoplasm, Residual 2Lymphoma, B-Cell, Marginal Zone 2Leukemia, Monocytic, Acute 2Leukemia, Biphenotypic, Acute 2Waldenstrom Macroglobulinemia 1Targeted Therapy 1Sarcoma, Myeloid 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Myeloproliferative Disorders 1Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Accelerated Phase 1Leukemia, B-Cell 1Hypereosinophilic Syndrome 1Hodgkin Disease 1Hematologic Diseases 1

Interventions

Rituximab 78Cyclophosphamide 76fludarabine phosphate 45Peripheral Blood Stem Cell Transplantation 41Mycophenolic Acid 39Tacrolimus 35Whole-Body Irradiation 33Radiotherapy 29Busulfan 29Cyclosporine 27Antilymphocyte Serum 27Etoposide 25Filgrastim 24Methotrexate 22Melphalan 22Lenalidomide 15Cytarabine 15Cord Blood Stem Cell Transplantation 14fludarabine 13Methylprednisolone 13Bortezomib 13orelabrutinib 12Dexamethasone 12sargramostim 11obinutuzumab 11Sirolimus 9Carmustine 9venetoclax 8Vincristine 8Prednisone 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Lymphoma, B-Cell, Marginal Zone × Cladribine × Clear all
NCT00980395 2019-12-30

VCR

University of Arizona

Phase 2 Completed
24 enrolled 11 charts
LymphoidOther hematologic neoplasm

Lymphoma, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT00656812 2013-12-24

Rituximab Plus 2CdA in Patients With Advanced or Relapsed Mucosa Associated Lymphoid Tissue (MALT) Lymphoma

Arbeitsgemeinschaft medikamentoese Tumortherapie

Phase 2 Completed
40 enrolled
Lymphoid

Lymphoma, B-Cell, Marginal Zone

Data powered by HemOnc (CC BY 4.0) Colophon âš¡